TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15683148

Group type: EXPERIMENTAL
Intervention: Watch_PAT100 (ambulatory device with built-in actigraph)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Watch_PAT100
Number of subjects: 228
Study: 11311997

Group type: EXPERIMENTAL
Intervention: Synthetic, monovalent, octameric HIV‐1 MN V3 peptide in aluminum hydroxide (alum) adjuvant administered by intramuscular delivery
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Oral administration of the vaccine (encapsulated in biodegradable micro‐spheres)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Combination of oral administration with parenteral boosting
Number of subjects: 33
Study: 9159559

Group type: EXPERIMENTAL
Intervention: Oral lamotrigine monotherapy for up to 48 weeks
Number of subjects: 163
Study: 8254181

Group type: EXPERIMENTAL
Intervention: Angiotensin II (1.5 ng/kg per min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sham infusion
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Angiotensin II (0.75 ng/kg per min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Angiotensin II (1.5 ng/kg per min) after indomethacin pretreatment
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Angiotensin II
Number of subjects: 8
Study: 3696929

Group type: EXPERIMENTAL
Intervention: Categorical order presentation of slides
Number of subjects: 10

Group type: COMPARATOR
Intervention: Random order presentation of slides
Number of subjects: 10
Study: 30063180

Group type: EXPERIMENTAL
Intervention: Pharmacological suppression of norepinephrine activity
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Pharmacological suppression of acetylcholine activity
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Centroparietal P3 component of the EEG
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Genetic factors (ADRA2A and NET genes)
Number of subjects: 154
Study: 26790036

Group type: EXPERIMENTAL
Intervention: 5% lidocaine gel
Number of subjects: 40

Group type: COMPARATOR
Intervention: 2% lidocaine gel
Number of subjects: 40
Study: 23849811

Group type: EXPERIMENTAL
Intervention: Immunomodulating Enteral Nutrition (IEN)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard Enteral Nutrition (SEN)
Number of subjects: 37
Study: 22806208

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.2 mg/day orally for 7 days)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 94
Study: 20510577

Group type: EXPERIMENTAL
Intervention: Attention training (n=20)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control procedures (n=21)
Number of subjects: 41
Study: 18717662

Group type: EXPERIMENTAL
Intervention: Portex reuseable bougie (R)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Portex single use bougie (S)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Temperature at 10 degrees C
Number of subjects: 16

Group type: COMPARATOR
Intervention: Temperature at 30 degrees C
Number of subjects: 16
Study: 17176661

Group type: EXPERIMENTAL
Intervention: Familiarity manipulation of alcohol-IAT target categories
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implicit Association Task (IAT)
Number of subjects: 0
Study: 15023660

Group type: EXPERIMENTAL
Intervention: LCPUFA supplementation of standard formula
Number of subjects: 0

Group type: COMPARATOR
Intervention: Breast milk
Number of subjects: 0
Study: 10678340

Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 45

Group type: COMPARATOR
Intervention: Diltiazem
Number of subjects: 45

Group type: COMPARATOR
Intervention: Beta-blockers
Number of subjects: 45

Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 45
Study: 8776832

Group type: EXPERIMENTAL
Intervention: 15 g pectin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 30 g pectin
Number of subjects: 6

Group type: COMPARATOR
Intervention: 0 g pectin
Number of subjects: 6
Study: 1468724

Group type: EXPERIMENTAL
Intervention: Prophylactic regimen 1
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Prophylactic regimen 2
Number of subjects: 219

Group type: COMPARATOR
Intervention: Both regimens
Number of subjects: 219
Study: 6385893

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation (PMR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention control (placebo)
Number of subjects: 0
Study: 30756302

Group type: EXPERIMENTAL
Intervention: Telephone coaching intervention
Number of subjects: 417

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 417
Study: 29654805

Group type: EXPERIMENTAL
Intervention: SER120 intranasal spray 0.83 mcg
Number of subjects: 1333

Group type: EXPERIMENTAL
Intervention: SER120 intranasal spray 1.66 mcg
Number of subjects: 1333

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1333
Study: 26251550

Group type: EXPERIMENTAL
Intervention: Caffeinated energy drink (3 mg of caffeine per kg of body mass)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo drink (no caffeine)
Number of subjects: 13
Study: 25280076

Group type: EXPERIMENTAL
Intervention: Virtual Environment (VE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional Paper Floor Plans (FPs)
Number of subjects: 30
Study: 22733922

Group type: EXPERIMENTAL
Intervention: Self-rated confidence in assessments by low-volume radiologists
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Self-rated confidence in assessments by high-volume radiologists
Number of subjects: 119
Study: 21375190

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (Group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Open appendectomy (Group A)
Number of subjects: 60
Study: 18044197

Group type: EXPERIMENTAL
Intervention: Intergenerational programming (IGP) with Montessori-based activities
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard activities programming
Number of subjects: 14
Study: 16562807

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition (PN) supplemented with glutamine (0.4 g/kg/day of L-alanine-L-glutamine)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard parenteral nutrition (PN)
Number of subjects: 49
Study: 12792701

Group type: EXPERIMENTAL
Intervention: 10 mg kg‐1 day‐1 ursodeoxycholic acid for three months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 10234869

Group type: EXPERIMENTAL
Intervention: Reflexological treatment for headache
Number of subjects: 220
Study: 8704351

Group type: EXPERIMENTAL
Intervention: Patellar ultrasound
Number of subjects: 1401

Group type: EXPERIMENTAL
Intervention: Forearm densitometry
Number of subjects: 1401

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1401
Study: 1655987

Group type: EXPERIMENTAL
Intervention: Three or four drugs plus whole-lung irradiation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Two or three drugs without whole-lung irradiation
Number of subjects: 32
Study: 6661381

Group type: EXPERIMENTAL
Intervention: Brotizolam (0.50 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flurazepam (30 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30698675

Group type: EXPERIMENTAL
Intervention: Pre-treatment genotyping (genotype-guided thiopurine dosing)
Number of subjects: 728

Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 728
Study: 27883215

Group type: COMPARATOR
Intervention: Adalimumab monotherapy
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Immunomodulator combination therapy
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Adalimumab combination therapy
Number of subjects: 1078
Study: 27382454

Group type: EXPERIMENTAL
Intervention: Deferasirox (DFX) - single oral daily dose of 20-40 mg/kg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Deferoxamine (DFO) - 20-50 mg/kg/day via subcutaneous infusion over 8-10 hours, 5 days a week
Number of subjects: 60
Study: 25009396

Group type: EXPERIMENTAL
Intervention: Portable endoscopy
Number of subjects: 129

Group type: COMPARATOR
Intervention: Nasogastric aspiration
Number of subjects: 129
Study: 21878578

Group type: EXPERIMENTAL
Intervention: 25 µg/h reservoir with heat
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 25 µg/h matrix with heat
Number of subjects: 5

Group type: COMPARATOR
Intervention: 50 µg/h reservoir without heat
Number of subjects: 5

Group type: COMPARATOR
Intervention: 25 µg/h reservoir without heat
Number of subjects: 5

Group type: COMPARATOR
Intervention: 25 µg/h matrix without heat
Number of subjects: 5
Study: 19246572

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 0
Study: 17205576

Group type: EXPERIMENTAL
Intervention: Hyaloglide
Number of subjects: 30

Group type: COMPARATOR
Intervention: No postsurgical treatment
Number of subjects: 30
Study: 15889357

Group type: EXPERIMENTAL
Intervention: Telavancin (administered intravenously once daily)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Standard therapy (antistaphylococcal penicillin 4 times daily or vancomycin twice daily)
Number of subjects: 167
Study: 11281611

Group type: EXPERIMENTAL
Intervention: Octreotide (0.1 mg sc) during exercise
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Exercise (30 minutes at 60% VO2max)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Octreotide (0.1 mg sc) after exercise
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Octreotide (0.1 mg sc) without exercise
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline during exercise
Number of subjects: 6

Group type: COMPARATOR
Intervention: No exercise with saline
Number of subjects: 6
Study: 9499947

Group type: EXPERIMENTAL
Intervention: Absorbable clip (laproclipR Davis and Geck)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Metal clips (titan clip ETHICONR)
Number of subjects: 100
Study: 7942182

Group type: EXPERIMENTAL
Intervention: Intravenous injection of interferon and ACNU in addition to radiotherapy (IAR therapy)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy with radiation and chemotherapy
Number of subjects: 175

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 175
Study: 2946583

Group type: COMPARATOR
Intervention: Prednisone 10 mg X 3 daily
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) orally 500 mg daily
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) i.m. 1000 mg daily for 3 weeks followed by 500 mg i.m. weekly
Number of subjects: 150
Study: 31856636

Group type: EXPERIMENTAL
Intervention: IDegLira
Number of subjects: 0

Group type: COMPARATOR
Intervention: IGlar U100
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basal-bolus therapy
Number of subjects: 0
Study: 29500582

Group type: EXPERIMENTAL
Intervention: Individual cognitive‐existential psychotherapy intervention for FCR (6-week duration)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 25
Study: 27930553

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) injection
Number of subjects: 26

Group type: COMPARATOR
Intervention: 0.9% sodium chloride injection
Number of subjects: 26

Group type: COMPARATOR
Intervention: Comparison between HA and control group
Number of subjects: 26
Study: 24785399

Group type: EXPERIMENTAL
Intervention: Community jury process
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 23993028

Group type: EXPERIMENTAL
Intervention: Low tidal volume (5 mL/kg + 5 cm H2O positive end-expiratory pressure) preserved ventilation (PV)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Conventional tidal volume (8 mL/kg) controlled ventilation (CV)
Number of subjects: 101
Study: 22010223

Group type: EXPERIMENTAL
Intervention: 2 mg/kg hydrogen sulfide from wk 0 to 3 and 3 mg/kg from wk 4 to 6
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: 4 mg/kg hydrogen sulfide from wk 0 to 3 and 6 mg/kg from wk 4 to 6
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: 8 mg/kg hydrogen sulfide from wk 0 to 3 and 12 mg/kg from wk 4 to 6
Number of subjects: 384

Group type: COMPARATOR
Intervention: Control group (no hydrogen sulfide added)
Number of subjects: 384
Study: 18312088

Group type: EXPERIMENTAL
Intervention: Coil embolization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clip ligation
Number of subjects: 0
Study: 16600069

Group type: EXPERIMENTAL
Intervention: Mind Reading software used at home for 10-15 weeks
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Mind Reading software used at home with weekly tutor sessions
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group of adults with AS/HFA (n = 22) assessed without intervention
Number of subjects: 19

Group type: COMPARATOR
Intervention: General population control group (n = 24 in Experiment 1, n = 13 in Experiment 2)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Social skills training for adults with AS/HFA
Number of subjects: 19
Study: 14717315

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 992

Group type: COMPARATOR
Intervention: Narcotic analgesia
Number of subjects: 992
Study: 11023563

Group type: EXPERIMENTAL
Intervention: Second attempt at ERCP
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: Advanced techniques for cannulation
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: ERCP with or without manometry
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: ERCP
Number of subjects: 562
Study: 19361146

Group type: EXPERIMENTAL
Intervention: Swim training at 60% of maximal heart rate reserve for 45 min per day, 3 days per week for 10 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Swim training
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (non-exercising)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Swim training and Control group
Number of subjects: 18
Study: 1404051

Group type: EXPERIMENTAL
Intervention: Percutaneous wiring based on the technique described by DePalma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment of manipulation and application of plaster of Paris
Number of subjects: 0
Study: 7152079

Group type: EXPERIMENTAL
Intervention: Alclometasone cream 0.05% applied twice a day for 21 days
Number of subjects: 31

Group type: COMPARATOR
Intervention: Clobetasone butyrate cream 0.5% applied twice a day for 21 days
Number of subjects: 31
Study: 31512572

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants' folate status
Number of subjects: 0
Study: 31039180

Group type: EXPERIMENTAL
Intervention: Walkasins turned ON
Number of subjects: 31

Group type: COMPARATOR
Intervention: Walkasins turned OFF
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Walkasins turned OFF-then-ON
Number of subjects: 31

Group type: COMPARATOR
Intervention: Walkasins turned ON-then-OFF
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Overall assessment
Number of subjects: 31
Study: 27677487

Group type: EXPERIMENTAL
Intervention: Protein-Enriched Diet (PED) with protein intake 2.0 g/kg of ideal body weight
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal Protein Diet (NPD) with protein intake 1.0 g/kg of ideal body weight
Number of subjects: 60
Study: 27233490

Group type: EXPERIMENTAL
Intervention: Blood transfusion
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Anemia (hemoglobin level ≤ 6.0 mmol/L or 9.7 g/dL)
Number of subjects: 415
Study: 24392746

Group type: EXPERIMENTAL
Intervention: Induction of labor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 0
Study: 22833684

Group type: EXPERIMENTAL
Intervention: Primary tumour resection plus systemic therapy
Number of subjects: 410

Group type: COMPARATOR
Intervention: Systemic therapy alone
Number of subjects: 410
Study: 18559131

Group type: EXPERIMENTAL
Intervention: Educational programme aimed at discouraging students from drinking sugar-sweetened beverages
Number of subjects: 1140

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1140
Study: 17584200

Group type: EXPERIMENTAL
Intervention: Pulsed‐wave tissue Doppler imaging (PW‐TDI)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 32
Study: 17064199

Group type: EXPERIMENTAL
Intervention: ICA-17043 50 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: ICA-17043 100 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: ICA-17043 150 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: ICA-17043
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 12588578

Group type: EXPERIMENTAL
Intervention: Exercise and incontinence care provided every 2 hours from 8:00 a.m. to 4:30 p.m. (total of four daily care episodes) 5 days a week for 32 weeks
Number of subjects: 190

Group type: COMPARATOR
Intervention: Usual care from nursing home staff
Number of subjects: 190
Study: 10228457

Group type: EXPERIMENTAL
Intervention: CMV infection
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: CMV disease
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Failure of renal graft
Number of subjects: 192
Study: 8934060

Group type: EXPERIMENTAL
Intervention: Norplant implants users
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 1751913

Group type: EXPERIMENTAL
Intervention: Transconjunctival cryopexy of the peripheral retina and vitreous base
Number of subjects: 16

Group type: COMPARATOR
Intervention: Systemic and periocular steroid therapy
Number of subjects: 16
Study: 7042090

Group type: EXPERIMENTAL
Intervention: Chemotherapy with MOPP and ABDV given in alternating months; Radiation therapy (RT) (2000 rad in 2 weeks) during Month 5
Number of subjects: 91
Study: 26840438

Group type: EXPERIMENTAL
Intervention: Compression Garments (CGs)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Regular gym shorts
Number of subjects: 18
Study: 28821315

Group type: EXPERIMENTAL
Intervention: Starch-entrapped microspheres (SM) 9 or 12 g
Number of subjects: 43

Group type: COMPARATOR
Intervention: Psyllium (12 g)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both SM and psyllium
Number of subjects: 43
Study: 26357934

Group type: EXPERIMENTAL
Intervention: Group S (supine position immediately after injection)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group L5 (lateral for 5 min then supine)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group L10 (lateral for 10 min then supine)
Number of subjects: 30
Study: 24083593

Group type: EXPERIMENTAL
Intervention: Treatment Region (TR)
Number of subjects: 200000

Group type: COMPARATOR
Intervention: Usual Care Region (UCR)
Number of subjects: 200000
Study: 22122001

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 90
Study: 18941065

Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced MRI before and after two cycles of chemotherapy
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced MRI
Number of subjects: 54
Study: 15983964

Group type: EXPERIMENTAL
Intervention: Peer mentoring
Number of subjects: 203

Group type: COMPARATOR
Intervention: Standard printed material
Number of subjects: 203
Study: 12508078

Group type: EXPERIMENTAL
Intervention: High amino acid intake (HAA) at 3 g.kg(‐1).d(‐1)
Number of subjects: 28
Study: 10624193

Group type: EXPERIMENTAL
Intervention: 3M Tegasorb dressing
Number of subjects: 90

Group type: COMPARATOR
Intervention: ConvaTec's Granuflex (E)
Number of subjects: 90
Study: 8558194

Group type: EXPERIMENTAL
Intervention: Fluorouracil (5FU) based chemotherapy: 200 mg/m2/d for 3 weeks with leucovorin 20 mg/m2/w, plus Cisplatin 100 mg/m2 on day 1
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Fluorouracil (5FU) based chemotherapy
Number of subjects: 65
Study: 1859765

Group type: EXPERIMENTAL
Intervention: Clonidine 0.2 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Clonidine 0.3 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Temazepam 20 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Clonidine 0.1 mg
Number of subjects: 80
Study: 6630314

Group type: EXPERIMENTAL
Intervention: Oral papaverine (600 mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Intravenous papaverine (100 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 30142023

Group type: EXPERIMENTAL
Intervention: Sleep condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wake condition
Number of subjects: 0
Study: 28833192

Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 0
Study: 25909546

Group type: EXPERIMENTAL
Intervention: Total myocardial revascularization
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Selective revascularization
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Elimination of ischemia in hibernating myocardium
Number of subjects: 131
Study: 23143142

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT), administered two times per week for 4 weeks, n = 12
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo group, n = 9
Number of subjects: 21
Study: 22947909

Group type: EXPERIMENTAL
Intervention: Atorvastatin and antihistamines
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo and antihistamines (Control group)
Number of subjects: 50
Study: 18926645

Group type: EXPERIMENTAL
Intervention: D-amphetamine (0, 15, and 30 mg/day)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Cocaine (4, 30, 60 mg, i.n.)
Number of subjects: 7

Group type: COMPARATOR
Intervention: D-amphetamine (30 mg/day)
Number of subjects: 7

Group type: COMPARATOR
Intervention: D-amphetamine (0 mg/day)
Number of subjects: 7
Study: 17698275

Group type: EXPERIMENTAL
Intervention: Quetiapine (up to 400 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 15
Study: 15010743

Group type: EXPERIMENTAL
Intervention: Warfarin (not specified dosage or duration)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Not anticoagulated
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Sinus rhythm maintenance
Number of subjects: 403
Study: 11223113

Group type: EXPERIMENTAL
Intervention: Psychogeriatric consultation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 9203245

Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride (300 mg single dose, 150 mg or 300 mg twice daily for 14 days)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride (150 mg twice daily)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride (300 mg twice daily)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Remacemide hydrochloride
Number of subjects: 17